Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet MHA, Nardone M, Rensen PCN, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
le Roux CW, Wharton S, Bozkurt B, et al.
Diabetes Obes Metab. Pub. online 4 Nov 2025.
Leggi
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings LK, Hsia S, Bays H, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
Percorso Executive di alta formazione in Digital and Future Health: AMD – Politecnico di Milano
Leggi
Social determinants of health and cancer prevention guideline behaviors
Chiang KE, Padilla HM, Callands TA, et al.
JAMA Netw Open. Pub. online 3 Nov 2025.
Leggi
Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes
Gitelman SE, Simmons K, Sherr JL, et al.
Diabetologia. Pub. online 6 Nov 2025.
Leggi
Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes
Henney AE, Heague M, Riley DR, et al.
Diabetes Obes Metab. Pub. online 3 Nov 2025.
Leggi
Role of circadian health in cardiometabolic health and disease risk: a scientific statement from the American Heart Association
Knutson KL, Dixon DD, Grandner MA, et al.
Circulation. Pub. online 28 Oct 2025.
Leggi
Systematic review and meta-analysis corrected for history of smoking tobacco identifies type 1 diabetes as a possible risk factor for bladder cancer
Bennett HO, Bogumil D, Kysh L, et al.
Diabetes Res Clin Pract. 2025:112976.
Leggi